Inhibition of Puerperal Lactation. A Double Blind Study of Bromocriptine and Placebo

Abstract

Bromocriptine and placebo were randomly MATERIAL AND METHODS allocated for three weeks to 52 postpartum patients requiring lactation suppression. Bromocriptine significantly lowered plasma prolactin levels and suppressed breast milk, breast pain and engorgement quicker than placebo. No side-effects were noted and rebound lactation did not occur. Menstruation appeared to re-start sooner when Bromocriptine was given.